XueBiJing Injection vs. Placebo for Critically Ill Patients with Severe Community-Acquired Pneumonia

journals.lww.com October 22, 2019

In critically ill patients with severe community-acquired pneumonia, XueBiJing injection led to a statistically significant improvement in the primary endpoint of the pneumonia severity index as well a significant improvement in the secondary clinical outcomes of mortality, duration of mechanical ventilation and duration of ICU stay.

XueBiJing, a Chinese herbal derived therapeutic, has been approved to treat severe infections (sepsis) in critically ill patients. XueBiJing has long been hypothesized to improve outcomes for serious lung infections in China. XueBiJing has potential mechanisms as an anti-inflammatory and an immune function enhancer.

The primary outcome was 8-day improvement in the pneumonia severity index risk rating.

Secondary outcomes were 28-day mortality rate, duration of mechanical ventilation and total duration of ICU stay.

Improvement in the pneumonia severity index risk rating, from a previously defined endpoint, occurred in 203 participants receiving XueBiJing and in 158 participants receiving placebo.

53 (15.87%) XueBiJing recipients and 84 (24.63%) placebo recipients died within 28 days.

Participants in the XueBiJing group received XueBiJing, 100 mL, q12 hours, and the control group received a visually indistinguishable placebo.